Goldman Sachs backs Ten K Solar

By Iris Dorbian — 4 weeks ago

Minneapolis-based Ten K Solar Inc, a provider of photovoltaic solutions for commercial rooftop, carports and ground-mount applications, has closed $25 million in funding. Goldman Sachs was the lead investor. Piper Jaffray advised Ten K Solar on the transaction.

Continue

Cortec acquires CVR Management

By Iris Dorbian — 1 month ago

Cortec Group has acquired Greenbelt, Maryland-based CVR Management, a management services provider to clinics that treat varicose and/or spider veins. No financial terms were disclosed. Piper Jaffray provided financial advice to CVR on the transaction.

Continue

NuVasive to buy VC-backed Ellipse for $380 mln

By Iris Dorbian — 1 month ago

NuVasive has agreed to acquire Ellipse Technologies Inc, a medical tech company focused on treating complex skeletal deformity, for $380 million. The transaction also includes a possible $30 million payout. Goldman Sachs is providing financial advice to NuVasive on the deal while Piper Jaffray is doing likewise for Ellipse. According to Crunchbase, Ellipse’s backers included BioStar Ventures, Wexford Capital and HBM BioVentures.

Continue

Piper Jaffray to buy investment bank Simmons

By Iris Dorbian — 3 months ago

Piper Jaffray has agreed to acquire Houston-based investment bank Simmons & Company International for a consideration of about $139 million. This amount includes $91 million in cash and $48 million in restricted stock. Berkshire Capital Securities LLC is acting as financial advisor to Simmons on the transaction. The deal is expected to close in the first quarter of 2016.

Continue

Voyager Therapeutics debuts IPO

By Iris Dorbian — 3 months ago

Cambridge, Massachusetts-based Voyager Therapeutics, a gene therapy company focused on treating central nervous system diseases, has raised $70 million for its IPO after pricing its five million shares at $14 per share. The stock began trading on the NASDAQ under the ticker symbol “VYGR.” Cowen and Company and Piper Jaffray & Co are the lead underwriters. Voyager’s backers included Brookside Capital, Partner Fund Management, Wellington Management Company LLP and Casdin Capital LLC.

Continue

Eureka exits Creative Co-Op stake

By Iris Dorbian — 3 months ago

Eureka Growth Capital has divested its stake in Creative Co-Op, a trade brand of Regent Holding Company, via a recapitalization backed by Freeman Spogli & Co. No financial terms were disclosed. Piper Jaffray was financial advisor to both Regent and Eureka on the transaction. Regent is a maker of home decor and accent products. PRESS […]

Continue

Halifax exits Caring Brands

By Iris Dorbian — 4 months ago

The Halifax Group has sold Sunrise, Florida-based Caring Brands International, a franchisor of home healthcare services. Levine Leichtman Capital Partners was the buyerNo financial terms were disclosed. Piper Jaffray and North Point Advisors advised Halifax and Caring Brands on the transaction.

Continue

VC-backed Aimmune Therapeutics goes public

By Iris Dorbian — 6 months ago

Brisbane, California-based Aimmune Therapeutics, a biopharmaceutical company focused on treating peanut allergies, has raised $160 million for its IPO after pricing its 10 million shares at $16 per share. The stock began trading Thursday on the NASDAQ under the ticker symbol “AIMT.” BofA Merrill Lynch, Credit Suisse and Piper Jaffray are serving as the lead underwriters. Aimmune’s backers include Longitude Capital, Foresite Capital and Aisling Capital.

Continue

Wynnchurch promotes four to MD

By Iris Dorbian — 7 months ago

Wynnchurch Capital has promoted Brian Crumbaugh, Greg Gleason, Neel Mayenkar and Michael Teplitsky to managing director. Prior to joining Wynnchurch, Crumbaugh worked at ShoreView Industries and Piper Jaffray while Gleason was at Houlihan Lokey and Bank of America. Mayenkar’s work background includes positions at Houlihan Lokey and at PricewaterhouseCoopers and Teplitsky’s resume has stints at Lime Rock Partners and at UBS Investment Bank.

Continue

VC-backed CoLucid goes public

By Iris Dorbian — 9 months ago

Durham, North Carolina-based CoLucid Pharmaceuticals, which develops oral lasmiditan that treats migraine headaches, has raised $55 million for its IPO after pricing its 5.5 million shares at $10 per share. The stock began trading Wednesday on the NASDAQ under the ticker symbol “CLCD.” Piper Jaffray & Co. and Stifel are serving as the lead underwriters. CoLucid’s backers include TVM Capital Life Science, Novo Ventures, Auriga Partners, Pappas Ventures, Domain Associates, Care Capital, Triathlon Medical Ventures and Pearl Street Ventures.

Continue

Catterton invests in Pure Barre

By Iris Dorbian — 9 months ago

Catterton has made a “significant” investment in fitness studio chain Pure Barre. No financial terms were disclosed. Pure Barre is backed by WJ Partners, which will remain an investor as a result of the transaction. Piper Jaffray & Co and Stephens Inc served as financial advisors to Pure Barre.

Continue

Kohlberg buys AM Conservation Group

By Iris Dorbian — 11 months ago

Kohlberg & Company LLC has acquired AM Conservation Group, a Charleston, South Carolina-based provider of energy and water efficiency programs and services. No financial terms were disclosed. Piper Jaffray was financial advisor to AM Conservation Group on the transaction while GE Antares Capital, Fifth Third Bank and Metropolitan Life Insurance Company provided credit financing.

Continue